Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities
Andrew Staron(Boston University), Vaishali Sanchorawala(Boston Medical Center), Gheorghe Doros(Boston University), Lawreen H. Connors(Boston University), Luke Zheng(Boston University)
Cited by 43
Related Papers
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
|American Journal of Hematology|2005|1.4k
High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study
|Annals of Internal Medicine|2004|615
Systemic immunoglobulin light chain amyloidosis
|Nature Reviews Disease Primers|2018|550
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis
|Leukemia|2012|383
Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38α MAPK pathway
|Proceedings of the National Academy of Sciences|2010|330